25th week of 2011 patent applcation highlights part 50 |
Patent application number | Title | Published |
20110150871 | TREATMENT OF AN AUTOIMMUNE DISEASE USING IL-18 ANTAGONISTS - The present invention relates to the field of autoimmune diseases, including rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Specifically, the invention relates to methods of treating autoimmune diseases in patients that are non-responsive or refractory over time to treatment with TNF-α antagonists and/or T-cell co-stimulation antagonists with an IL-18 antagonist. | 2011-06-23 |
20110150872 | SOLUBLE HETERODIMERIC CYTOKINE RECEPTOR - A soluble receptor that binds to IL-20 having two polypeptide subunits, IL-22R and IL-20RB. The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond. | 2011-06-23 |
20110150873 | ANTI-INFLAMMATORY COMPOSITIONS AND COMBINATIONS - The invention relates to the use of Broad-Spectrum Chemokine Inhibitors (BSCIs), and in particular members of the acylaminolactam class of pharmaceutical agents, for the prevention, prophylaxis, treatment or amelioration of symptoms of inflammatory diseases. In particular, improved compositions consisting of BSCI agents combined with one or more additional active pharmaceutical agents in order to achieve improved anti-inflammatory efficacy with a reduced side-effect profile are described and claimed. | 2011-06-23 |
20110150874 | FUSION PROTEINS, USES THEREOF AND PROCESSES FOR PRODUCING SAME - This invention provides fusion proteins comprising consecutive amino acids which beginning at the amino terminus of the protein correspond to consecutive amino acids present in (i) a cytomegalovirus human MHC-restricted peptide, (ii) a first peptide linker, (iii) a human β-2 microglobulin, (iv) a second peptide linker, (v) a HLA-A2 chain of a human MHC class I molecule, (vi) a third peptide linker, (vii) a variable region from a heavy chain of a scFv fragment of an antibody, and (viii) a variable region from a light chain of such scFv fragment, wherein the consecutive amino acids which correspond to (vii) and (viii) are bound together directly by a peptide bond or by consecutive amino acids which correspond to a fourth peptide linker, wherein the antibody from which the scFv fragment is derived specifically binds to mesothelin. This invention provides nucleic acid constructs encoding same, processes for producing same, compositions, and uses thereof. | 2011-06-23 |
20110150875 | EGF-A DOMAIN-MEDIATED MODULATION OF PCKS9 FOR TREATING LIPID DISORDERS - The present invention provides, in part, methods and compositions for treating lipid disorders comprising administering a polypeptide that inhibits PCSK9. A novel method for identifying polypeptides that interact with PCSK9 is also provided. | 2011-06-23 |
20110150876 | Prognosis and Treatment of Breast Cancer - The present invention relates to an antibody which specifically binds a Spot 14 (S14 or THRSP) protein in human breast cancer cells and a method for using the same to predict disease-free survival and select treatment modalities for breast cancer. The present invention is also a method for inducing apoptosis in breast cancer cells by inhibiting the expression or activity of Spot 14. Compositions and methods for treating breast cancer are also provided. | 2011-06-23 |
20110150877 | EPHRIN-B RECEPTOR PROTEIN INVOLVED IN CARCINOMA - The present invention provides a polypeptide (CCMP-1) of use in the diagnosis, screening, treatment and prophylaxis of carcinoma. Also provided are compositions comprising the protein, vaccines and antibodies that are immunospecific for the protein. | 2011-06-23 |
20110150878 | COMPOSITIONS AND METHODS FOR MANIPULATING LEVELS OF ANTIGEN-SPECIFIC ANTIBODIES IN A MAMMAL - The invention provides compositions and methods for increasing the levels of an autoantigen-specific IgM antibody in a mammal and, thus, decreasing the levels of a circulating autoantigen in a mammal. Using these autoantigen-specific IgM antibodies, the invention provides compositions and methods for ameliorating an autoimmune disease in a mammal. In one aspect, the invention provides compositions and methods for increasing the levels of an antigen-specific IgG antibody in a mammal and, thus, decreasing the levels of a circulating antigen in a mammal. Using these antigen-specific IgG antibodies, the invention provides compositions and methods for ameliorating a disease or condition in a mammal, e.g., a cancer or a foreign antigen, such as a pathogen. | 2011-06-23 |
20110150879 | SPECIFIC DEPLETION OF CD4+ T CELLS - Specific depletion or modulation of activity of CD4 | 2011-06-23 |
20110150880 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES - The invention relates to the compositions of synthetic oligo-β-(1→6)-2-amino-2-deoxy-D-glucopyranosides conjugated to carriers, and methods for making and use same. | 2011-06-23 |
20110150881 | INHIBITORS OF EXTRACELLULAR HSP90 - The present invention describes inhibitors of extracellular Hsp90. The inhibition of extracellular Hsp90 leads to a reduction of the invasiveness of the tumor cells. Furthermore, the invention relates to the use of molecules inhibiting extracellular Hsp90 function for the manufacture of a medicament for the treatment or prevention of invasion and/or metastatic potential of cancer cells. | 2011-06-23 |
20110150882 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAN CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer. | 2011-06-23 |
20110150883 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer. | 2011-06-23 |
20110150884 | CRYSTALLINE COMPOSITION OF GM-CSF/GM-CSFR - The present invention relates generally to the field of crystallography. More particularly, the present invention provides crystalline forms of a complex between granulocyte macrophage-colony stimulating factor (GM-CSF) and its receptor (GM-CSFR). The present invention further provides methods for the design and selection of modulators of GM-CSF/GM-CSFR interaction and signaling as well as signaling of other cytokines. | 2011-06-23 |
20110150885 | AMINOACYL TRNA SYNTHETASES FOR MODULATING HEMATOPOIESIS - Hematopoietic-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof, as well as compositions comprising related agents such as antibodies and other binding agents. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of hematopoiesis. | 2011-06-23 |
20110150886 | ANTI-AREG/HB-EGF ANTIBODIES AND TREATMENT - Described are cross-specific antibody molecules with binding specificity for both AREG and HBEGF. The antibody molecules may be used in methods of treatment of cancer and diseases associated with angiogenesis. | 2011-06-23 |
20110150887 | METHODS AND PRODUCTS RELATING TO GSK3BETA REGULATION - The invention relates to methods and compositions for regulation of GSK | 2011-06-23 |
20110150888 | ANTI-HEPCIDIN ANTIBODIES AND METHODS OF USE - The invention relates to monoclonal antibodies that bind hepcidin and methods of making and using such antibodies. Also provided are methods of treating hepcidin-related disorders. | 2011-06-23 |
20110150889 | HAEMOPHILUS INFLUENZAE TYPE IV PILI - The invention described herein relates to a | 2011-06-23 |
20110150890 | USE OF CGRP ANTAGONIST COMPOUNDS FOR TREATMENT OF PSORIASIS - The invention provides methods and compositions for treating, preventing and/or remedying psoriasis, based on compounds that have a calcitonin-related gene peptide (CGRP) antagonistic effect. Methods are also disclosed for identifying compounds with CGRP antagonist activity which thereby are suitable candidate compounds for treating psoriasis. | 2011-06-23 |
20110150891 | Methods of Treating Interstitial Cystitis - The present invention relates to the use of adalimumab (Humira™), for the treatment of a pain and/or a lower urinary tract symptom(s) (LUTS) associated with interstitial cystitis and/or painful bladder syndrome and/or bladder pain syndrome. | 2011-06-23 |
20110150892 | HUMAN ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen- specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti- LAG-3 antibody is co-administered with at least one additional immuno stimulatory antibody, is also provided. | 2011-06-23 |
20110150893 | ANTI-TRKB MONOCLONAL ANTIBODIES AND USES THEREOF - The present invention provides monoclonal antibodies for human TrkB. In certain embodiments the inventive antibodies bind and activate human TrkB. In certain embodiments the inventive antibodies are selective for human TrkB in that they do not bind (or activate) human TrkA or human TrkC. In some embodiments the inventive monoclonal antibodies cross-react with murine TrkB. Humanized or veneered versions of the inventive antibodies are also encompassed. Pharmaceutical compositions that comprise inventive antibodies are provided as are methods for preparing the inventive antibodies and methods of using these for treatment, detection or purification purposes. | 2011-06-23 |
20110150894 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 - The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and/or the intracellular signaling from TRPV4 via β1 integrin activation. | 2011-06-23 |
20110150895 | ANTIBODY SPECIFICALLY BINDING TO ANGIOPOIETIN-2 AND USE THEREOF - An antibody specifically binding to angiopoietin-2, and antigen-binding fragments thereof, and a use thereof are disclosed. | 2011-06-23 |
20110150896 | Antibody against PCRV - Provided is an effective means for therapy of infection, particularly infection with | 2011-06-23 |
20110150897 | INFLUENZA TARGETS - The present invention relates to pharmaceutical compositions comprising modulators of kinases, kinase binding polypeptides or/and an inhibitor for influenza virus replication for the prevention or/and treatment of influenza. | 2011-06-23 |
20110150898 | EPHA2 as a therapeutic target for cancer - The present invention is directed to compounds and methods for the treatment of metastatic disease. The compounds of this invention have specificity for EphA2, an epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. The compounds used in accordance with this invention may be provided in a pharmaceutical composition for treatment of metastatic disease. | 2011-06-23 |
20110150899 | SENESCENCE CONTROL COMPOSITION CONTAINING EXTRACELLULAR MATRIX COMPONENTS, AND SENESCENCE CONTROL METHOD FOR SENESCENT CELLS USING SAME - The present invention relates to a composition containing an extracellular matrix for controlling aging and a method for controlling aging by using the same. The composition for controlling aging and the method for controlling aging have an effect for recovering the biological function of the aged aging cell, and the amount of the expression of the integrin alpha V that is a cell membrane protein and is reduced if aging is again increased in the aging cell recovered by the young extracellular matrix. However, when the amount of expression of the integrin alpha V is artificially decreased by using siRNA and antibody, the aging cell is not recovered by the extracellular matrix extracted from the young cell. | 2011-06-23 |
20110150900 | REGULATION OF FATTY ACID TRANSPORTERS - The present invention provides materials and methods for modulating FATP expression and/or activity in vivo. The materials and methods have numerous diagnostic, prophylactic, and therapeutic applications for various diseases and conditions that are influenced by FATPs, or characterized by excessive or inadequate FATP expression or activity. | 2011-06-23 |
20110150901 | BINDING PROTEINS THAT BIND TO HUMAN FGFR1C, HUMAN BETA-KLOTHO AND BOTH HUMAN FGFR1C AND HUMAN BETA-KLOTHO - Binding proteins that specifically bind to β-Klotho or portions thereof, FGFR1c or portions thereof, or both FGFR1c and β-Klotho, and optionally other proteins as well are provided. Coding sequences, methods of treatment and pharmaceutical compositions are also provided. | 2011-06-23 |
20110150902 | TREATING CANCER - This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided. | 2011-06-23 |
20110150903 | FGF-R4 RECEPTOR-SPECIFIC ANTAGONISTS - The present invention relates to FGF-R4 receptor-specific antagonist molecules enabling the inhibition of the activity of said receptor. Said antagonists are, particularly, FGF-R4-specific antibodies enabling the inhibition of the activity of said receptor. The present invention also relates to the therapeutic use of said antibodies, particularly in the field of angiogenesis and in the treatment of certain types of cancer. | 2011-06-23 |
20110150904 | Therapeutic Antibodies for Treatment and Prophylaxis of Transmittable Viral Diseases - The invention provides methods and compositions for the treatment and prevention of a transmittable disease in a subject, such as avians and mammals. The methods and compositions of the invention specifically make use of avian antibodies to the disease to be treated or prevented. Administration of such avian antibodies to a subject has been shown effective for reducing mortality in a population of subjects that are infected, or become infected, with the disease. The invention also provides kits useful for detecting the presence of transmittable diseases in subjects. | 2011-06-23 |
20110150905 | HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4 - The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the K | 2011-06-23 |
20110150906 | BINDING MEMBER WHICH BINDS TO BOTH LEWIS-Y AND LEWIS-B HAPTENS, AND ITS USE FOR TREATING CANCER - The invention relates to the use of a binding member which binds to Lewis | 2011-06-23 |
20110150907 | METHODS AND MATERIALS FOR GASTROINTESTINAL DELIVERY OF PATHOGEN/TOXIN BINDING AGENTS - The present disclosure relates generally to recombinant bacteria (e.g., | 2011-06-23 |
20110150908 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER AND IMMUNE DISORDERS - Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions. | 2011-06-23 |
20110150909 | Yeast-Based Vaccines As Immunotherapy - Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed. | 2011-06-23 |
20110150910 | METHODS OF INDUCING AN IMMUNE RESPONSE - Novel genes designated and set forth in FIG. | 2011-06-23 |
20110150911 | Methods and reagents for treating, preventing and diagnosing bunyavirus infection - Immunogenic compositions for use in treating, preventing and diagnosing infection caused by the California (CAL) serotype of the genus | 2011-06-23 |
20110150912 | Avian influenza virus live attenuated vaccine and uses thereof - Described in this application are attenuated strains of avian influenza virus containing temperature sensitive mutations in addition to a genetic tag in the PB1 gene. The attenuated viruses are useful as avian and mammalian vaccine for protective immunity against homologous and heterologous lethal challenges with influenza virus. A genetically modified avian influenza virus backbone is described which can be used as a master donor strain for the generation of live attenuated vaccines for epidemic and pandemic influenza. | 2011-06-23 |
20110150913 | TORQUE TENO VIRUS (TTV) ISOLATES AND COMPOSITIONS - The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen. | 2011-06-23 |
20110150914 | COMPOSITIONS AND METHODS FOR DENGUE VIRUS (DV) TREATMENT AND VACCINATION - The invention relates to Dengue virus (DV) peptides and compositions thereof, and methods that employ Dengue virus (DV) peptides and compositions thereof. The invention includes among other things, methods of treating Dengue virus (DV) infection or pathology, which include, for example, administering Dengue virus (DV) peptide T cell epitope, to treat a Dengue virus (DV) infection or pathology. The invention includes among other things Dengue virus (DV) vaccination and immunization methods. | 2011-06-23 |
20110150915 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 2011-06-23 |
20110150916 | COMPOSITIONS AND METHODS FOR TREATMENT OF GROUP A STREPTOCOCCI - Immunogenic compositions and vaccines are described comprising GAS Markers including AtmB Proteins. Methods for detecting GAS diseases in a subject are also described comprising measuring GAS markers or antibodies against GAS markers in a sample from the subject. The invention further provides kits for carrying out the methods of the invention and therapeutic applications for GAS diseases employing GAS markers, polynucleotides encoding the markers, and/or binding agents for the markers. | 2011-06-23 |
20110150917 | Small Cationic Antimicrobial Peptides - Cationic bacteriocin and lantibiotic peptides are provided and their immunomodulatory activities are described. Methods are provided for selectively enhancing innate immunity. Other methods are provided for selectively suppressing a proinflammatory response. Other methods are provided for identifying a compound or compounds which modulate an innate immune response. Pharmaceutical compositions comprising the cationic bacteriocin and lantibiotic peptides or polynucleotides are also provided. | 2011-06-23 |
20110150918 | TREATMENT OF MICROBIAL INFECTIONS - The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including Staphylococcal origin. Ideally, the present invention is directed to a recombinant staphylococcal MSCRAMM or MSCRAMM-like proteins, or fragment thereof, with reduced binding to its host ligand, for use in therapy. | 2011-06-23 |
20110150919 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer. | 2011-06-23 |
20110150920 | Allergy Vaccines Containing Hybrid Polypeptides - Hybrid polypeptides comprising at least two different allergenic proteins or fragments thereof wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein are disclosed. The hybrid polypeptides and polynucleotides coding therefor can be used as pharmaceutical compositions, in particular as vaccines. | 2011-06-23 |
20110150921 | NOVEL FUSION PROTEINS AND USE THEREOF FOR PREPARING HEPATITIS C VACCINES - An immunogenic fusion protein includes at least, on the C-terminal side, a first peptide composed of the S protein deleted of the transmembrane domain thereof located at the N-terminal end thereof, of a hepatitis B virus (HBV) isolate, and on the N-terminal side, a second peptide composed of the transmembrane domain and of the ectodomain of at least one envelope protein of a hepatitis C virus (HCV) isolate. A hybrid nucleic acid molecule encoding the fusion protein, and a vector including the hybrid nucleic acid molecule, a subviral particle including the fusion protein, an immunogenic composition including at least the fusion protein, or at least the hybrid nucleic acid molecule, or at least the subviral particle, and a cell line for the production of the fusion protein, or of the hybrid nucleic acid molecule, or of the subviral particle are described. | 2011-06-23 |
20110150922 | IMMUNOGEN PLATFORM - Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines. | 2011-06-23 |
20110150923 | MUCOSAL MENINGOCOCCAL VACCINES - The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of | 2011-06-23 |
20110150924 | Device, Method, and system for neural modulation as vaccine adjuvant in a vertebrate subject - A method for enhancing an immune response in a vertebrate subject is described. The method includes providing at least one energy stimulus configured to modulate one or more nervous system components of the vertebrate subject, and administering one or more immunogen to the vertebrate subject, wherein the at least one energy stimulus and the one or more immunogen are provided in a combination and in a temporal sequence sufficient to enhance an immune response in the vertebrate subject. | 2011-06-23 |
20110150925 | CELL-BASED SYSTEMS FOR PRODUCING INFLUENZA VACCINES - The present invention relates to a cell-based method for producing influenza virus vaccines by enriching the population of surface-bound α2,6-sialic acid receptors on a cell surface, such as on a Chinese Hamster Ovary (CHO) cell surface. The host cell therefore presents numerous binding sites to which an influenza virus can bind via its hemagglutinin spike protein and infect the host cell. In contrast to wild-type CHO cells, the surface of the mutated CHO cells of the present invention contains an enriched population of α2,6-sialic acid receptors which makes the inventive CHO cells highly susceptible to viral infection, and therefore safe, effective, and highly efficient cells for rapidly producing influenza vaccines. | 2011-06-23 |
20110150926 | INFLUENZA VACCINES - The invention relates to a method for the treatment or prevention of an influenza virus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a gamma-irradiated influenza virus. | 2011-06-23 |
20110150927 | Stabilisation of Viral Microparticles - A micro-particulate dry powder composition comprising a viral particle can be prepared by spray-drying a mixture of the viral particle and a stabilizing carbohydrate using an outlet temperature of no more than 60° C. | 2011-06-23 |
20110150928 | UNIQUE AVIAN REOVIRIDAE - This invention relates to novel unique strains avian reoviridae that were isolated from severe cases of Runting Stunting Syndrome. The present invention also relates to the isolation and uses of novel unique avian reoviridae, diagnostic assays using nucleotide or amino acid specific components of such viruses, such as the sequence encoding Sigma C capsid protein and to vaccines that protect birds from diseases caused by such viruses. | 2011-06-23 |
20110150929 | SARS vaccine compositions and methods of making and using them - Described is a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases such as SARS, in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating immunogenic modified, partially delipidated viral particles with reduced infectivity. The present invention provides delipidated viral vaccine compositions, such as therapeutic vaccine compositions, comprising these modified, partially delipidated viral particles with reduced infectivity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism or, in case of a therapeutic vaccine, to treat or alleviate infection against the lipid-containing infections viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and/or one or more types of virus. | 2011-06-23 |
20110150930 | Recombinant viral-based malaria vaccines - Described are vaccines against malarial infections, which are based on recombinant viral vectors, such as alpha viruses, adenoviruses, or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different | 2011-06-23 |
20110150931 | RAPID RESPONSES TO DELAYED BOOSTER IMMUNISATIONS - Booster immunization can lead to rapid induction of protective immunity against pathogens (e.g. ≦7 days after the booster dose). This rapid response means that booster immunization can be used at short notice prior to an event that might require an activated immune response. For instance, a subject can be primed at a young age against a pathogen that typically affects more elderly subjects under specific circumstances such that, when the subject is older, the immune response can be mobilized rapidly if those specific circumstances are expected. An example would be to prime a subject against infections that are typically acquired nosocomially and then, soon before a scheduled hospital appointment, to boost their immune response so that they enter hospital in an immune-alert state. | 2011-06-23 |
20110150932 | Constructing a DNA Chimera for Vaccine Development Against Leishmaniasis and Tuberculosis - A novel recombinant chimera of DNA construct having esat-6 region of | 2011-06-23 |
20110150933 | CATTLE VACCINES - This document provides live non-pathogenic | 2011-06-23 |
20110150934 | Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer - Disclosed are compositions comprising non-viable ovarian tumor cells and/or ovarian cancer tissue cells useful as a vaccine for human ovarian cancer and/or for the inhibition of human ovarian tumor growth. Methods for preparing the ovarian cancer and/or tumor vaccines that comprise these compositions are also provided, as well as methods of using the vaccines in the treatment and/or inhibition of tumor growth, and particularly ovarian tumor growth and ovarian cancers. The preparations may be defined as vaccines comprising human ovarian tumor tissue cells and/or human ovarian cancer cells. Preparations comprising the ovarian tissue cells together with an adjuvant are also provided. The ovarian tumor and/or ovarian cancer vaccines are demonstrated to significantly reduce the incidence of autochthonous ovarian cancer. | 2011-06-23 |
20110150935 | TARGETED TREATMENT FOR PATIENTS WITH ESTROGEN RECEPTOR NEGATIVE AND PROGESTERONE RECEPTOR NEGATIVE BREAST CANCERS - Treatments for estrogen receptor and progesterone receptor negative breast cancer or estrogen receptor, progesterone receptor and c-erbB2 negative (triple negative) breast cancer are provided. | 2011-06-23 |
20110150936 | ANTI-TUMORAL CELLS - The present invention relates to the field of preventive or therapeutic anti-tumoral vaccine. More specifically, the present invention relates to live animal tumour cells having a negative MHC-I phenotype, to methods for the production of such MHC-I negative cells, and to their therapeutic use as anti-tumoral agents, particularly via their capacity to activate natural killer (NK) cells. The invention further relates to methods for modulating the level of expression of MHC-I molecules on animal tumour cells, for example by use of specific culture conditions, and/or by use of exogenous agents which directly or indirectly affect levels of MHC-I expression. The invention also concerns activated NK cells and their therapeutic use as anti-tumoral agents. | 2011-06-23 |
20110150937 | EXTENDED RELEASE COMPOSITIONS COMPRISING TOLTERODINE - The present invention deals with extended release pharmaceutical composition comprising tolterodine, wherein the composition comprises of: a) a drug layer comprising of drug tolterodine tartrate, monosaccharide and/or disaccharide on an inert core; or a drug core comprising of drug tolterodine tartrate, monosaccharide and/or disaccharide; and b) a polymer layer comprising of extended release polymer(s). The invention also provides a process for the preparation of the above mentioned composition. | 2011-06-23 |
20110150938 | Supercrystalline Colloidal Particles and Method of Production - The present invention concerns size- and shape-controlled, colloidal superparticles (SPs) and methods for synthesizing the same. Ligand-functionalized nanoparticles such as nonpolar-solvent-dispersible nanoparticles, are used, and the solvophobic interactions can be controlled. Advantageously, supercrystalline SPs having a superlattice structure, such as a face-centered cubic structure, can be produced. Further, the methods of the invention can provide SPs that self-assemble and are monodisperse. The SPs can be doped with organic dyes and further assembled into more complex structures. | 2011-06-23 |
20110150939 | Compositions for removing stains from dental surfaces, and methods of making and using the same - A composition for removing stains from dental surfaces comprising a stain removing effective amount of at least two active components selected from a peroxide compound, a polyphosphate, and an anionic surfactant, in combination with an orally acceptable carrier. The present invention is further directed to methods of making and using the same. | 2011-06-23 |
20110150940 | DRY POWDER COMPOSITIONS AND SYSTEMS FOR POULTRY VACCINATION - This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or non-reducing sugar and a biocompatible polymer, said dry powder composition being in the form of particles having an average particle size from 2 to 30 μm and a particle size polydispersity from 1.1 to 4.0. This invention also relates to a method for producing said dry powder compositions and a system for vaccination of poultry by inhalation. | 2011-06-23 |
20110150941 | EPITHELIAL DELIVERY - The present invention relates to composition comprising vesicles and associated with the vesicles, a chemical agent, for use in a method of treatment by therapy wherein the chemical agent is delivered trans- and/or intra-epithelially to a human or animal body, wherein the constructs comprise an amphiphilic block copolymer having a hydrophilic and a hydrophobic block. | 2011-06-23 |
20110150942 | GASTRO-RESISTANT PHARMACEUTICAL ORAL COMPOSITIONS COMPRISING DULOXETINE OR ITS PHARMACEUTICALLY ACCEPTABLE DERIVATIVES - The present invention relates to a pharmaceutical composition comprising an active core comprising duloxetine or its pharmaceutically acceptable derivatives, a separating layer comprising a pH modifier and a gastro-resistant coating comprising a gastro-resistant polymer selected from methacrylic acid copolymers and optionally an over-coating layer. The present invention also relates to a process for the preparation of duloxetine hydrochloride. It also relates to a packaged medicament. | 2011-06-23 |
20110150943 | ADHESIVE FOR MEDICAL APPLICATIONS AND MEANS FOR HAEMOSTASIS - The invention relates to adhesives for medical applications and methods of their preparation and use. | 2011-06-23 |
20110150944 | STRUCTURED TRIGLYCERIDES AND EMULSIONS COMPRISING SAME - The present invention relates to structured triglycerides, to parenteral nutrition emulsions of the same, and uses thereof. In particular, the invention relates to structured triglycerides that include at least one medium chain C | 2011-06-23 |
20110150945 | ORAL PHARMACEUTICAL FORMULATION FOR OMEPRAZOLE COMPRISING A SPECIFIC SEPARATION LAYER - The invention relates to an enteric coated oral pharmaceutical formulation comprising, as the active ingredient, omeprazole, an alkaline salt of omeprazole, an enantiomer of omeprazole, or an alkaline salt of an enantiomer of omeprazole, and a specific separation layer between active ingredient and enteric coating comprising a polyvinyl alcohol/polyethylene glycol graft copolymer and/or optionally modified pea starch. | 2011-06-23 |
20110150946 | Transdermal Delivery of Apomorphine Using Microneedles - The present invention relates generally to methods for transdermal delivery of a therapeutically effective amount of apomorphine using microneedles. The invention also provides methods for treatment of erectile dysfunction and Parkinson's disease using apomorphine hydrochloride or any pharmaceutically acceptable salt, and/or apomorphine prodrugs to the microneedle-treated site. | 2011-06-23 |
20110150947 | Cosmetic Compositions Comprising Fibrous Pigments - Cosmetic compositions comprising a fibrous pigment having an average diameter greater than 0.2 microns and an average aspect ratio greater than 5, and methods of using said compositions for imparting a pigmented film on skin or imparting a lightening appearance of skin are provided. The compositions optionally comprise from 0.1 to 30% of a coloring agent, selected from pigments, lakes, and dyes. The appearance of skin to which the compositions have been topically applied as a cosmetic film possesses L*, a*, and b* color space values and angular reflection properties closer to those of natural skin than an identical composition wherein the fibrous pigment has an average aspect ratio of less than 5. | 2011-06-23 |
20110150948 | COLORED MICRONIZED SPHERICAL POLYMER POWDER AND COSMETIC COMPOSITION THEREOF - The present invention provides a colored micronized polymer powder for the use in cosmetics, the powder comprising at least one polymer wherein the particles of the colored micronized polymer powder having a spherical shape and an average particle size in the range of 0.1 to 100 μm. The present invention provides also a cosmetic composition comprising the at least one colored micronized polymer powder according to the invention. | 2011-06-23 |
20110150949 | Liquid Cleaning And/Or Cleansing Composition - The present invention relates to a liquid, cleaning and/or cleansing composition comprising abrasive cleaning particles, wherein said abrasive cleaning particles comprise a divinyl benzene cross-linked styrene polymer, wherein said abrasive cleaning particles are non-spherical and have a mean particles size D(v,0.9) of at least about 10 μm and wherein said liquid, cleaning and/or cleansing composition comprises from about 0% to about 30% by weight of the composition of an organic solvent. | 2011-06-23 |
20110150950 | Liquid Cleaning And/Or Cleansing Composition - The present invention relates to a liquid, cleaning and/or cleansing composition comprising abrasive cleaning particles. | 2011-06-23 |
20110150951 | Liquid Cleaning And/Or Cleansing Composition - The present invention relates to a liquid, cleaning and/or cleansing composition comprising abrasive cleaning particles. | 2011-06-23 |
20110150952 | EXTEMPORANEOUS CARE PRODUCT BASED ON A LYOPHILIZATE OF MICROORGANISMS AND SURFACTANT(S) WITH AN HLB GREATER THAN OR EQUAL TO 12 - The present invention relates to a method for the cosmetic treatment of a keratin material comprising at least the steps of: (a) having available a lyophilizate containing at least one live or inactivated, physiologically acceptable microorganism, one of its metabolites or one of its fractions and at least one surfactant with an HLB greater than or equal to 12, (b) having available a physiologically acceptable medium, separate from the said lyophilizate, (c) bringing the said lyophilizate extemporaneously into contact with the said medium under conditions favourable for the solubilization and/or dispersion of the said lyophilizate in the said medium, and (d) bringing the mixture obtained in the preceding step into contact with the said keratin material. It further relates to a lyophilizate as defined above. | 2011-06-23 |
20110150953 | METHOD FOR PRODUCING VESICLE, VESICLE OBTAINED BY THE PRODUCTION METHOD, AND W/O/W EMULSION FOR PRODUCING VESICLE - A vesicle is produced by: a step of producing a W/O emulsion from an aqueous solution containing a substance to be entrapped in a vesicle in a dissolved or suspended state and an organic solvent phase containing a lipid having emulsification capacity, which can constitute the vesicle; a step of producing a W/O/W emulsion from the W/O emulsion and an external water phase solution of a water-soluble emulsifier, which does not destroy a vesicle lipid membrane; and a step of removing the organic solvent phase from the W/O/W emulsion, so as to form a vesicle. This method simultaneously achieves a high entrapment yield of an active ingredient and the control of a particle diameter. | 2011-06-23 |
20110150954 | AGENT-ENCAPSULATING MICRO-AND NANOPARTICLES, METHODS FOR PREPARATION OF SAME AND PRODUCTS CONTAINING SAME - Substantially leachless, agent-encapsulating sol-gel particles, methods of preparing same and products containing same are provided. | 2011-06-23 |
20110150955 | Products and Methods for Reducing Malodor from the Pudendum - Products and methods are disclosed for reducing the production of unwanted odors from the pudendum. | 2011-06-23 |
20110150956 | Immobilized 1,2-benzisothiazolin-3-one - The present invention provides novel antimicrobial immobilized 1,2-benzisothiazolin-3-one/zinc oxide (BIT/ZnO) complexes useful as antimicrobial agents because of their resistance to being leached from the substrate to which they are attached. The present invention is also directed to methods for preparing the BIT/ZnO complexes, to BIT/ZnO complexes prepared by the novel methods, to methods for using the BIT/ZnO complexes to inhibit microbial growth or reduce the level of bacteria on the surface of a substrate, and to substrates protected to from microbial attack by being treated with the BIT/ZnO complexes. The present invention is further directed to compositions comprising 1,2-benzisothiazolin-3-one which has been immobilized with zinc oxide. | 2011-06-23 |
20110150957 | Method Of Controlling Soil Insects - The present invention relates to an insecticidal granular composition, comprising (a) at least one insecticide, selected from the group consisting of an enaminocarbonyl compound, a neonicotinoid, a tetronic acid derivative or a tetramic acid derivative compound, a carbamate compound, an organophosphate compound, a diamide compound, a pyrethroid compound and flonicamid; (b) optionally at least one moisture-retaining agent; and (c) vegetable meal. | 2011-06-23 |
20110150958 | CHLORHEXIDINE ACETATE ANTISEPTIC CLEANING AGENT - An antiseptic cleaning agent, generally, comprising chlorhexidine acetate and a solvent, such as an alcohol and/or water. The chlorhexidine acetate acts as a highly effective biocide. Additionally, the chlorhexidine acetate allows the cleaning agent to dry without leaving a tacky residue. Where the cleaning agent comprises one or more alcohols, the alcohols may comprise any suitable alcohols, including lower alcohols having from 1 to 6 carbon atoms, such as ethanol and isopropanol. Where the ratio of ethanol to isopropanol may be from between about 1:1000 to about 1000:1. In addition to chlorhexidine acetate, the cleaning agent optionally comprises another non-alcohol biocide, such as triclosan. The cleaning agent can be used in any suitable manner. For instance, the cleaning agent may be impregnated in an absorbent material, such as a towelette, swabstick, or gauze. Additionally, the absorbent material may comprise a positively charged or a non-ionic substance, such as polypropylene or polyester. | 2011-06-23 |
20110150959 | WIPE WITH ODOUR CONTROL SUBSTANCE - A wipe, in particular a personal hygiene wipe such as a baby care, feminine hygiene care, incontinence care, hand care or foot care wipe, includes a composition including oxidized lipids as an odour control substance. The lipids are oxidized under controlled conditions to have a peroxide value of at least 20 meq/kg. The lipids are for example triglycerides of fatty acids. | 2011-06-23 |
20110150960 | HAZARDOUS SUBSTANCE REMOVING MATERIAL AND METHOD FOR REMOVING HAZARDOUS SUBSTANCE - It is an object of the present invention to provide a hazardous substance removing material, which efficiently captures hazardous substances derived from microorganisms such as bacteria or viruses and rapidly inactivates them, so as to minimize the their influences on human bodies, and which is able to allow an antibody to be supported on a carrier by a simple method, and which has an improved antibody use efficiency. The present invention provides a hazardous substance removing material consisting of a carrier on which an antibody and a sugar chain affinity substance having an affinity for a sugar chain in the Fc region of the antibody are supported. | 2011-06-23 |
20110150961 | ANTI-INFECTIVE CATHETERS - Anti-infective catheters are provided. Such catheters comprise a composition that comprises a pyrimidine analog, polyurethane, and cellulose or a cellulose-derived polymer, for example, in form of a coating. In addition, anti-infective compositions and methods of making and using anti-infective catheters are provided. | 2011-06-23 |
20110150962 | THERAPEUTIC AGENT CAPSULE FOR IMPLANTS - The present invention discloses a system for releasing one or more therapeutic agents contained within a capsule onto or into an implant. At least one capsule is inserted in a recess preferably located along a longitudinal axis of the implant. The at least one adhesive capsule may be inserted in the recess and held in place therein by a holder. A plurality of adhesive capsules and holders may be inserted in one or more recesses located substantially along the longitudinal axis of the implant. The at least one capsule preferably has a casing housing one or more therapeutic agents, wherein the capsule is configured to be pierced by the at least one fastener to release the one or more therapeutic agents. The casing of the capsule may form an annular passageway to receive a guide wire for aiding the insertion of the capsule in an implant having a longitudinal bore along at least a portion thereof. | 2011-06-23 |
20110150963 | BIOACTIVE ANTIBACTERIAL BONE GRAFT MATERIALS - The present invention generally relates to bioactive antibacterial materials and composites that enhance bone growth while preventing surgical site infection. The present invention also relates to bioactive antibacterial materials and composites that include a bimodal bioactive glass particle size distribution. The bioactive antibacterial composite finds utility in a variety of clinical applications including spine and orthopaedic procedures. | 2011-06-23 |
20110150964 | APTAMER-COATED IMPLANT, PROCESS OF PRODUCTION, AND USES - One embodiment of the present invention is an implant with an aptamer coating, wherein the aptamer has an activating effect on the α | 2011-06-23 |
20110150965 | MEDICAL DEVICES HAVING ADHERENT POLYMERIC LAYERS WITH DEPTH-DEPENDENT PROPERTIES - According to one aspect of the invention, a method of forming a medical device is provided, which includes: (a) contacting a substrate with a solution that contains (i) one or more types of polymers, (ii) a solvent that contains one or more types of solvent species, and (iii) one or more optional agents, for example, one or more therapeutic agents, among others; and (b) removing the solvent from the solution, thereby forming a polymeric layer on the substrate. The composition of the solution is changed over the course of forming the polymeric layer. In another aspect of the invention, a medical device is provided, which includes a substrate and a polymeric layer over the substrate. The polymeric layer contains a copolymer that contains differing first and second monomers. The lower surface of the polymeric layer contacting the substrate has a surface concentration of the first monomer relative to the second monomer that is higher than that of the upper surface of the polymeric layer opposite the substrate. | 2011-06-23 |
20110150966 | DEGRADABLE POLYMERS INCORPORATING GAMMA-BUTYROLACTONE - Disclosed herein are implantable medical devices having controlled release biodegradable polymer coatings thereon wherein the polymer is formed from ring opening of γ-butyrolactone and at least one additional monomer selected from the group consisting of trimethylene carbonate, lactide, polyethylene glycol, glycolide, the monomers formed from ring opening of ε-caprolactone, 4-tert-butyl caprolactone, and N-acetyl caprolactone, and combinations thereof, and at least one drug releasable from the biodegradable polymer. Also disclosed are implantable medical devices form of the biodegradable polymers and processes for forming the polymers. | 2011-06-23 |
20110150967 | METHOD OF REDUCING INCIDENCE OF INTRAOCULAR PRESSURE ASSOCIATED WITH INTRAOCULAR USE OF CORTICOSTEROIDS - A method of treating an ocular disease in a subject using a corticosteroid with reduced incidence of intraocular pressure lowering surgery comprises injecting an intravitreal insert capable of providing a therapeutic effect for an extended period of time. The intravitreal insert delivers sustained sub-microgram levels of corticosteroid. | 2011-06-23 |
20110150968 | DISSOLVABLE DIETARY SUPPLEMENT STRIP AND METHODS FOR USING THE SAME - A strip, which is both edible and dissolvable, is provided comprising a film and a dosage of at least 2% of the reference daily intake (RDI) of at least one dietary supplement for malnutrition or to prevent/treat alcohol induced hangovers. A method for treating malnutrition and/or preventing and treating alcohol-induced hangovers using a dissolvable orally administered strip. | 2011-06-23 |
20110150972 | MEDICAL DEVICES HAVING IMPROVED PERFORMANCE - According to an aspect of the present invention, medical devices are provided that contain at least one polymeric region which contains (a) at least one block copolymer that contains at least at least three polymer blocks that differ from one another and (b) at least one therapeutic agent. | 2011-06-23 |
20110150973 | ELECTROSPUN DEXTRAN FIBERS AND DEVICES FORMED THEREFROM - The invention generally relates to dextran fibers which are preferably electrospun and devices formed from such fibers. In particular, such devices may include substances of interest (such as therapeutic substances) associated with the electrospun fibers. Upon exposure to a liquid the electrospun fibers dissolve immediately and the substances of interest are released into the liquid. Exemplary devices include bandages formed from electrospun dextran fibers and associated agents that promote hemostasis, such as thrombin and fibrinogen. | 2011-06-23 |